HLUBF (H. Lundbeck AS) Inventories, Inventories Adjustments : $0 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Inventories, Inventories Adjustments?

H. Lundbeck AS's Inventories, Inventories Adjustments for the quarter that ended in Sep. 2024 was $0 Mil.

H. Lundbeck AS Inventories, Inventories Adjustments Historical Data

The historical data trend for H. Lundbeck AS's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Inventories, Inventories Adjustments Chart

H. Lundbeck AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Inventories Adjustments

Get a 7-Day Free Trial

H. Lundbeck AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Inventories Adjustments	Get a 7-Day Free Trial															-	-	-	-	-

H. Lundbeck AS Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

H. Lundbeck AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OTCPK:HLUBF) » Definitions » Inventories, Inventories Adjustments

Comparable Companies

Traded in Other Exchanges

HLBBF:USA HLUNBc:UK 0ABR:UK 0ND5:UK HLUN A:Denmark HLUN B:Denmark LDBB:Germany LUNB:Austria

Address

Ottiliavej 9, Valby, DNK, 2500

Website

https://www.lundbeck.com

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.